<DOC>
	<DOCNO>NCT03010423</DOCNO>
	<brief_summary>The study single-center , interventional , pilot study evaluate improvement microvascular function positron emission tomography ( PET ) twelve-week treatment oral nicorandil female non-obstructive CAD subject .</brief_summary>
	<brief_title>Efficacy Study Oral Nicorandil Improving Microvascular Function Female Non-obstructive Coronary Artery Disease ( CAD ) Subjects</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Nicorandil</mesh_term>
	<criteria>Inclusion criterion : Female Subjects age 1870 year Subjects typical stable angina without coronary obstruction ( define coronary occlusion less ( &lt; ) 20 % ) invasive coronary angiography coronary compute tomography angiography ( CTA ) recent three month STsegment horizontal downward slop equal ( &gt; = ) 0.1 millivolt ( mV ) electrocardiogram ( ECG ) exercise stress test angina attack ; positive result adenosine stress myocardial perfusion tomographic image recent three month All long act cardiovascular disease medicine , include limited aspirin/clopidogrel , CCB , ACEI/ARB , betablockers , statin , ivabradine , trimetazidine , et al , stable take least one month screen period For Subjects meet five criterion , MFR test stress PET . Subjects whose MFR &lt; 2.5 could include study Exclusion criterion : Severe uncontrolled hypertension ( rest Systolic blood pressure [ SBP ] &gt; =160 millimeter mercury ( mmHg ) , rest Diastolic blood pressure [ DBP ] &gt; =100mmHg screen period ) Subjects shock ( include cardiogenic shock ) , hypovolemia Severe hypotension ( rest SBP &lt; 90mmHgï¼Œor rest DBP &lt; 60mmHg ) Significant valvular heart disease , congenital heart disease cardiomyopathy Congestive heart failure ( New York Heart Association [ NYHA ] IIIIV ) , echocardiographic ejection fraction &lt; 45 % Acute pulmonary edema ; Hepatic renal dysfunction , define : Serum Alanine Aminotransferase ( ALT ) &gt; triple normal value upper limit ; Serum Aspartate Aminotransferase ( AST ) &gt; triple normal value upper limit Serum creatinine &gt; twice normal value upper limit Glaucoma Active peptic ulcer active skin ulcer Taking glyburide , phosphodiesterase type 5 ( PDE5 ) inhibitor , soluble guanylate cyclase stimulator ( ) Known hypersensitivity nicorandil , nitrate , niacin , excipient With contraindication complete stress PET test No legal ability legal ability limited Subjects unlikely cooperate study inability unwillingness give inform consent Childbearing period woman without effective contraceptive measure , pregnancy lactation Participation another clinical trial within past 30 day Other significant disease Investigator 's opinion would exclude subject trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-obstructive coronary artery disease</keyword>
	<keyword>Nicorandil</keyword>
</DOC>